Cosentyx is a prescription medication that is used to treat certain autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein called interleukin-17A that is involved in the inflammation process. While Cosentyx is generally considered safe and effective, like all medications, it may cause some side effects, including potential risks to the heart.

According to a study published in the Journal of the American College of Cardiology [2], patients taking Cosentyx had a higher risk of major adverse cardiovascular events (MACE) than those taking a placebo. The study found that 0.5% of patients taking Cosentyx experienced a MACE, compared to 0.1% of patients taking a placebo. However, it's important to note that the overall risk of MACE was still relatively low, and the study authors noted that more research is needed to fully understand the cardiovascular risks associated with Cosentyx.

Another study published in the journal Rheumatology [3] found that patients with pre-existing cardiovascular disease who were taking Cosentyx did not experience any significant changes in their cardiovascular health over a 24-week period. However, the study was small and short-term, so more research is needed to confirm these findings.

It's important to note that Cosentyx should not be used by patients with active infections or a history of allergic reactions to any of the ingredients in the medication. Patients with a history of inflammatory bowel disease, multiple sclerosis, or other autoimmune diseases may also be at increased risk of side effects from Cosentyx.

Overall, while there may be some potential risks to the heart associated with Cosentyx, the overall risk is still relatively low. Patients taking Cosentyx should be monitored closely by their healthcare provider for any signs of cardiovascular problems, and should report any symptoms such as chest pain, shortness of breath, or palpitations immediately. As with any medication, patients should weigh the potential benefits against the potential risks before starting treatment with Cosentyx.

Sources:
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412670/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701232/
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[4] https://www.medicalnewstoday.com/articles/326632